Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and
radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for …

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type,
characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with the
highest mortality, for which survival has hardly changed in the last 40 years. This high …

Abstract Introduction National Comprehensive Cancer Network (NCCN) 2019 Guidelines
recommend universal germline (GL) testing for patients (pts) with pancreatic cancer (PC) …

Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important
applications in management of multiple types of gastrointestinal cancers. Different …

Neoadjuvant chemotherapy is considered a new treatment option for potentially resectable
pancreatic cancer. However, data are not well established on overall survival and delaying …

Simple Summary The use of liquid biopsy for tumor genomic profiling to identify genomic
biomarkers for targeted therapies has revolutionized the clinical practice in oncology …

Simple Summary Gastrointestinal (GI) cancers are a common cancer, affecting both men
and women, normally diagnosed through tissue biopsies in combination with imaging …

Comprehensive molecular landsca** studies reveal a potentially brighter future for
pancreatic ductal adenocarcinoma (PDAC) patients. Blood-borne biomarkers obtained from …

This systematic review and meta-analysis evaluated the prognostic role of cell-free DNA
(cfDNA) in pancreatic ductal adenocarcinoma (PDAC). Eligible studies reported differences …